References
- The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary artery disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339(19): 1349–57
- Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/T exCAPS. JAMA 1998; 279(20): 1615–22
- The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383–9
- Garnett WR. Interactions with hydroxylmethylglutaryl-coenzyme A reductase inhihitors. Am J Health Syst Pharm 1995; 52(15): 1639–45
- Gibson OM, Yang BB, Abel RB, et al. Effects of hepatic and renal impairment on pharmacokinetics and pharmacodynamics of atorvastatin. Pharm Res 1996; 13 Suppl: 428
- Pravachol package insert. Princeton, NJ: Bristol Meyers Squihh, April 1997
- Lescol package insert. East Hanover, NJ: Sandoz (Novartis), June 1998
- Zocor package insert. West Point, Pa: Merck, Jan 1998
- Baycol package insert. West Haven, Conn: Bayer, July 2000